Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGFtriggered,erlotinib-resistant lung cancer harboring an EGFR mutation

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

Martinez-Marti, Alex
Felip, Enriqueta
Matito, Judit
Mereu, Elisabetta
Navarro, A.
Cedrés, S.
Pardo, N.
Martines de Castro, Ana
Remon, Jordi
Miquel, J.M.
Guillaumet-Adkins, Amy
Nadal, E.
Rodríguez Esteban, Gustavo
Arqués, O.
Fasani, R.
Nuciforo, Paolo G.
Heyn, Holger
Villanueva, Alberto
Palmer, Héctor G.
Vivancos Prellezo, Ana

BACKGROUND: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)...

Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors

Szokol, B.
Gyulavari, P.
Kurko, I.
Baska, F.
Szantai-Kis, C.
Greff, Z.
Örfi, Z.
Petak, I.
Penzes, K.
Torka, R.
Ullrich, A.
Örfi, L.
Vantus, T.
Keri, G.

April 2014

Activating mutations in the epidermal growth factor receptor (EGER) have been identified in a subset...

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

Koizumi, Hitomi
Yamada, Tadaaki
Takeuchi, Shinji
Nakagawa, Takayuki
Kita, Kenji
Nakamura, Takahiro
Matsumoto, Kunio
Suda, Kenichi
Mitsudomi, Tetsuya
Yano, Seiji

July 2012

Introduction:The three major clinically relevant mechanisms of acquired resistance to epidermal grow...

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation

Nakade, Junya
Takeuchi, Shinji
Nakagawa, Takayuki
Ishikawa, Daisuke
Sano, Takako
Nanjo, Shigeki
Yamada, Tadaaki
Ebi, Hiromichi
Zhao, Lu
Yasumoto, Kazuo
Matsumoto, Kunio
Yonekura, Kazuhiko
Yano, Seiji

June 2014

Introduction:Met activation by gene amplification and its ligand, hepatocyte growth factor (HGF), im...

Therapeutic Discovery Combined TherapywithMutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Takayuki Nakagawa
Shinji Takeuchi
Tadaaki Yamada
Shigeki Nanjo
Daisuke Ishikawa
Takako Sano
Kenji Kita
Takahiro Nakamura
Kunio Matsumoto
Kenichi Suda
Tetsuya Mitsudomi
Yoshitaka Sekido
Toshimitsu Uenaka
Seiji Yano

October 2016

Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) erlotinib and gefitinib have shown d...

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

Mancini, M
Gaborit, N
Lindzen, M
Salame, Tm
Sevilla Sharon, M
Abdul Hai, A
Downward, J
Yarden, Y.
DALL'ORA, MASSIMILIANO

January 2015

Despite initial responses to targeted kinase inhibitors, lung cancer patients presenting with primar...

Generation EGFR Inhibitors to Overcome Resistance to

Shigeki Nanjo
Tadaaki Yamada
Hiroshi Nishihara
Shinji Takeuchi
Takako Sano
Daisuke Ishikawa
Lu Zhao
Hiromichi Ebi
Kazuo Yasumoto
Kunio Matsumoto

October 2016

Purpose: Although EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have shown dramatic effects aga...

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells

Dario Presutti (828288)
Simonetta Santini (828289)
Beatrice Cardinali (120407)
Giuliana Papoff (688457)
Cristiana Lalli (687846)
Simone Samperna (828290)
Valentina Fustaino (828291)
Giuseppe Giannini (120417)
Giovina Ruberti (687850)

November 2015

<div><p>Epidermal growth factor receptor (EGFR), member of the human epidermal growth factor recepto...

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Mancini, Maicol
Gal, Hilah
Gaborit, Nadège
Mazzeo, Luigi
Romaniello, Donatella
Salame, Tomer,
Lindzen, Moshit
Mahlknecht, Georg
Enuka, Yehoshua
Ga Burton, Dominick
Roth, Lee
Noronha, Ashish
Marrocco, Ilaria
Adreka, Dan
Altstadter, Raya,
Bousquet, Emilie
Downward, Julian
Maraver, Antonio
Krizhanovsky, Valery
Yarden, Yosef

February 2018

International audienceEpidermal growth factor receptor (EGFR) mutations identify patients with lung ...

Synergy Between Kinase Inhibitors And Antibodies Enables Upfront Prevention Of Recurring Secondary Resistance In Egfr-Mutated Lung Cancer

February 2022

none9siNSCLC (non-small cell lung cancer) patients harboring activating mutations (i.e., exon 19 del...

An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors

Marrocco I. (ORCID:0000-0002-8225-2177)

January 2018

Epidermal growth factor receptor (EGFR) mutations identify patients with lung cancer who derive bene...

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.

Lara, Matthew S
Holland, William S
Chinn, Danielle
Burich, Rebekah A
Lara, Primo N
Gandara, David R
Kelly, Karen
Mack, Philip C

May 2017

BackgroundAlthough the epidermal growth factor receptor (EGFR) inhibitor erlotinib is initially effe...

Combined Treatment with Erlotinib and a Transforming Growth Factor-β Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells

Serizawa, Masakuni
Takahashi, Toshiaki
Yamamoto, Nobuyuki
Koh, Yasuhiro

March 2013

IntroductionDespite an initial dramatic response to the epidermal growth factor receptor (EGFR) tyro...

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Turke, Alexa B.
Zejnullahu, Kreshnik
Wu, Yi-Long
Song, Youngchul
Dias-Santagata, Dora
Lifshits, Eugene
Toschi, Luca
Rogers, Andrew
Mok, Tony
Sequist, Lecia
Lindeman, Neal I.
Murphy, Carly
Akhavanfard, Sara
Yeap, Beow Y.
Xiao, Yun
Capelletti, Marzia
Iafrate, A. John
Lee, Charles
Christensen, James G.
Engelman, Jeffrey A.
Jänne, Pasi A.

January 2010

SummaryMET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and causes r...

Ability of the met kinase inhibitor crizotinib and new generation EGFR Inhibitors to overcome resistance to EGFR inhibitors. Plos One 8: doi:10.1371/journal.pone.0084700

Shigeki Nanjo
Tadaaki Yamada
Hiroshi Nishihara
Shinji Takeuchi
Takako Sano
Daisuke Ishikawa
Lu Zhao
Hiromichi Ebi
Kazuo Yasumoto
Kunio Matsumoto

January 2013

Purpose: Although EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have shown dramatic effects aga...

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

Martinez-Marti, Alex
Felip, Enriqueta
Matito, Judit
Mereu, Elisabetta
Navarro, A.
Cedrés, S.
Pardo, N.
Martines de Castro, Ana
Remon, Jordi
Miquel, J.M.
Guillaumet-Adkins, Amy
Nadal, E.
Rodríguez Esteban, Gustavo
Arqués, O.
Fasani, R.
Nuciforo, Paolo G.
Heyn, Holger
Villanueva, Alberto
Palmer, Héctor G.
Vivancos Prellezo, Ana

BACKGROUND: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)...

Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors

Szokol, B.
Gyulavari, P.
Kurko, I.
Baska, F.
Szantai-Kis, C.
Greff, Z.
Örfi, Z.
Petak, I.
Penzes, K.
Torka, R.
Ullrich, A.
Örfi, L.
Vantus, T.
Keri, G.

April 2014

Activating mutations in the epidermal growth factor receptor (EGER) have been identified in a subset...

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

Koizumi, Hitomi
Yamada, Tadaaki
Takeuchi, Shinji
Nakagawa, Takayuki
Kita, Kenji
Nakamura, Takahiro
Matsumoto, Kunio
Suda, Kenichi
Mitsudomi, Tetsuya
Yano, Seiji

July 2012

Introduction:The three major clinically relevant mechanisms of acquired resistance to epidermal grow...

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation

Nakade, Junya
Takeuchi, Shinji
Nakagawa, Takayuki
Ishikawa, Daisuke
Sano, Takako
Nanjo, Shigeki
Yamada, Tadaaki
Ebi, Hiromichi
Zhao, Lu
Yasumoto, Kazuo
Matsumoto, Kunio
Yonekura, Kazuhiko
Yano, Seiji

June 2014

Introduction:Met activation by gene amplification and its ligand, hepatocyte growth factor (HGF), im...

Therapeutic Discovery Combined TherapywithMutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Takayuki Nakagawa
Shinji Takeuchi
Tadaaki Yamada
Shigeki Nanjo
Daisuke Ishikawa
Takako Sano
Kenji Kita
Takahiro Nakamura
Kunio Matsumoto
Kenichi Suda
Tetsuya Mitsudomi
Yoshitaka Sekido
Toshimitsu Uenaka
Seiji Yano

October 2016

Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) erlotinib and gefitinib have shown d...

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

Mancini, M
Gaborit, N
Lindzen, M
Salame, Tm
Sevilla Sharon, M
Abdul Hai, A
Downward, J
Yarden, Y.
DALL'ORA, MASSIMILIANO

January 2015

Despite initial responses to targeted kinase inhibitors, lung cancer patients presenting with primar...

Generation EGFR Inhibitors to Overcome Resistance to

Shigeki Nanjo
Tadaaki Yamada
Hiroshi Nishihara
Shinji Takeuchi
Takako Sano
Daisuke Ishikawa
Lu Zhao
Hiromichi Ebi
Kazuo Yasumoto
Kunio Matsumoto

October 2016

Purpose: Although EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have shown dramatic effects aga...

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells

Dario Presutti (828288)
Simonetta Santini (828289)
Beatrice Cardinali (120407)
Giuliana Papoff (688457)
Cristiana Lalli (687846)
Simone Samperna (828290)
Valentina Fustaino (828291)
Giuseppe Giannini (120417)
Giovina Ruberti (687850)

November 2015

<div><p>Epidermal growth factor receptor (EGFR), member of the human epidermal growth factor recepto...

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Mancini, Maicol
Gal, Hilah
Gaborit, Nadège
Mazzeo, Luigi
Romaniello, Donatella
Salame, Tomer,
Lindzen, Moshit
Mahlknecht, Georg
Enuka, Yehoshua
Ga Burton, Dominick
Roth, Lee
Noronha, Ashish
Marrocco, Ilaria
Adreka, Dan
Altstadter, Raya,
Bousquet, Emilie
Downward, Julian
Maraver, Antonio
Krizhanovsky, Valery
Yarden, Yosef

February 2018

International audienceEpidermal growth factor receptor (EGFR) mutations identify patients with lung ...

Synergy Between Kinase Inhibitors And Antibodies Enables Upfront Prevention Of Recurring Secondary Resistance In Egfr-Mutated Lung Cancer

February 2022

none9siNSCLC (non-small cell lung cancer) patients harboring activating mutations (i.e., exon 19 del...

An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors

Marrocco I. (ORCID:0000-0002-8225-2177)

January 2018

Epidermal growth factor receptor (EGFR) mutations identify patients with lung cancer who derive bene...

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.

Lara, Matthew S
Holland, William S
Chinn, Danielle
Burich, Rebekah A
Lara, Primo N
Gandara, David R
Kelly, Karen
Mack, Philip C

May 2017

BackgroundAlthough the epidermal growth factor receptor (EGFR) inhibitor erlotinib is initially effe...

Combined Treatment with Erlotinib and a Transforming Growth Factor-β Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells

Serizawa, Masakuni
Takahashi, Toshiaki
Yamamoto, Nobuyuki
Koh, Yasuhiro

March 2013

IntroductionDespite an initial dramatic response to the epidermal growth factor receptor (EGFR) tyro...

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Turke, Alexa B.
Zejnullahu, Kreshnik
Wu, Yi-Long
Song, Youngchul
Dias-Santagata, Dora
Lifshits, Eugene
Toschi, Luca
Rogers, Andrew
Mok, Tony
Sequist, Lecia
Lindeman, Neal I.
Murphy, Carly
Akhavanfard, Sara
Yeap, Beow Y.
Xiao, Yun
Capelletti, Marzia
Iafrate, A. John
Lee, Charles
Christensen, James G.
Engelman, Jeffrey A.
Jänne, Pasi A.

January 2010

SummaryMET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and causes r...

Ability of the met kinase inhibitor crizotinib and new generation EGFR Inhibitors to overcome resistance to EGFR inhibitors. Plos One 8: doi:10.1371/journal.pone.0084700

Shigeki Nanjo
Tadaaki Yamada
Hiroshi Nishihara
Shinji Takeuchi
Takako Sano
Daisuke Ishikawa
Lu Zhao
Hiromichi Ebi
Kazuo Yasumoto
Kunio Matsumoto

January 2013

Purpose: Although EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have shown dramatic effects aga...

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

Martinez-Marti, Alex
Felip, Enriqueta
Matito, Judit
Mereu, Elisabetta
Navarro, A.
Cedrés, S.
Pardo, N.
Martines de Castro, Ana
Remon, Jordi
Miquel, J.M.
Guillaumet-Adkins, Amy
Nadal, E.
Rodríguez Esteban, Gustavo
Arqués, O.
Fasani, R.
Nuciforo, Paolo G.
Heyn, Holger
Villanueva, Alberto
Palmer, Héctor G.
Vivancos Prellezo, Ana

BACKGROUND: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)...

Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors

Szokol, B.
Gyulavari, P.
Kurko, I.
Baska, F.
Szantai-Kis, C.
Greff, Z.
Örfi, Z.
Petak, I.
Penzes, K.
Torka, R.
Ullrich, A.
Örfi, L.
Vantus, T.
Keri, G.

April 2014

Activating mutations in the epidermal growth factor receptor (EGER) have been identified in a subset...

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

Koizumi, Hitomi
Yamada, Tadaaki
Takeuchi, Shinji
Nakagawa, Takayuki
Kita, Kenji
Nakamura, Takahiro
Matsumoto, Kunio
Suda, Kenichi
Mitsudomi, Tetsuya
Yano, Seiji

July 2012

Introduction:The three major clinically relevant mechanisms of acquired resistance to epidermal grow...

Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGFtriggered,erlotinib-resistant lung cancer harboring an EGFR mutation

Abstract

Extracted data

Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGFtriggered,erlotinib-resistant lung cancer harboring an EGFR mutation

Abstract

Extracted data

Related items

Related items